启迪药业(000590) - 2018 Q1 - 季度财报

Financial Performance - Revenue for Q1 2018 was ¥59,179,800.24, a decrease of 17.13% compared to ¥71,411,609.76 in the same period last year[8] - Net profit attributable to shareholders was ¥5,457,422.00, down 49.03% from ¥10,706,913.39 year-on-year[8] - Net profit excluding non-recurring gains and losses was ¥3,617,144.06, a decline of 56.15% compared to ¥8,249,083.63 in the previous year[8] - Basic earnings per share decreased by 52.40% to ¥0.0228 from ¥0.0479 in the same period last year[8] - Net profit attributable to shareholders decreased by 49.03% to ¥5,457,422.00, mainly due to a decline in main business revenue[15] - Basic earnings per share fell by 52.40% to ¥0.0228, resulting from reduced net profit and an increase in total share capital[15] Assets and Liabilities - Total assets at the end of the reporting period were ¥845,280,333.93, down 3.26% from ¥873,736,015.88 at the end of the previous year[8] - Net assets attributable to shareholders increased by 0.94% to ¥588,788,574.96 from ¥583,331,152.96 at the end of the previous year[8] - Cash and cash equivalents decreased by 32.71% to ¥83,623,389.01, primarily due to reduced net cash flow from operating activities[16] - Other receivables increased by 300.06% to ¥6,122,421.14, mainly due to an increase in payments to units and individuals[16] - Construction in progress rose by 78.40% to ¥6,144,158.71, driven by increased investment in the oral liquid technology upgrade project[16] Cash Flow - The net cash flow from operating activities was -¥36,691,589.68, an improvement from -¥69,424,718.77 in the previous year[8] - Cash received from operating activities decreased by 50.79% to ¥773,216.96, mainly due to reduced cash inflows related to operating activities[16] Expenses - Sales expenses decreased by 33.29% to ¥9,229,521.20 due to the exclusion of Gu Han Medicine from the consolidated financial statements[15] - Financial expenses reduced by 54.35% to -¥404,596.82 primarily due to a decrease in discounted acceptance bills[15] - Tax payments increased by 111.35% to ¥20,198,263.15, reflecting higher tax obligations during the reporting period[16] Shareholder Information - The top shareholder, Tsinghua Tongfang Co., Ltd., holds 29.41% of shares, totaling 70,432,904 shares[11] - The total number of ordinary shareholders at the end of the reporting period was 12,021[11] Other Information - The company received government subsidies amounting to ¥172,957.50 during the reporting period[9] - The company reported a commitment to lock-up shares for 36 months from May 24, 2017, for newly issued shares from a private placement, which is currently being fulfilled[21] - There are no significant changes in the company's net profit expected for the first half of 2018 compared to the same period last year[23] - The company has not engaged in any securities or derivative investments during the reporting period[24][26] - There were no violations regarding external guarantees during the reporting period[26] - The company has not reported any non-operating fund occupation by controlling shareholders or their affiliates[28]